Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma

International Journal of Cancer

Volumn 72, Issue 3, 1997, Pages 424-430

  Blay, Jean Yves ^a   Rossi, Jean François ^b   Wijdenes, John ^c   Menetrier Caux, Christine ^a   Schemann, Stéphane ^a   Nérier, Sylvie ^a   Philip, Thierry ^a   Favrot, Marie ^a  

^a CENTRE LÉON BÉRARD   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c Diaclone   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PARANEOPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ALKALINE PHOSPHATASE; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CHOLESTASIS; FEMALE; HAPTOGLOBINS; HUMANS; IMMUNORADIOMETRIC ASSAY; INFLAMMATION; INTERLEUKIN-6; KIDNEY NEOPLASMS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PARANEOPLASTIC SYNDROMES; PLATELET COUNT;

EID: 0030796001     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R     Document Type: Article

References (30)

1. BATAILLE, R., BARLOGIE, B., ZHAO, Y.-L., ROSSI, J.F., LAVABRE-BERTRAND, T., BECK, T., WIJDENES, J., BROCHIER, J. and KLEIN, B., Biologic effects of anti-IL-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86, 685-691 (1995).
2. BLAY, J.-Y., BOLON, I., ALBERTI, L., WIJDENES, J. and FAVROT, M.C., 1L-6 as an intracellular growth factor in renal-cell carcinoma. Proc. Amer. Ass. Cancer Res., 35, 615 (1994a).
3. BLAY, J.Y., NEGRIER, S., COMBARET, V., ATTALI, S., GOILLOT, E., MERROUCHE, Y., MERCATELLO, A., RAVAULT, A., TOURANI, J.M., MOSKOVTCHENKO, J.F., PHILIP, T. and FAVROT, M.C., Serum level of interleukin 6 as a prognosis factor in metastatic renal-cell carcinoma. Cancer Res., 52, 3317-3322 (1992a).
4. BLAY, J.-Y. NEGRIER, S., COMBARET, V., ATTALI, S., MERCATELLO, A., MOSKOVTCHENKO, J.-F., PHILIP, T. and FAVROT, M.C., Analyse des variations des taux sériques des cytokines pro-inflammatoires au cours de l'administration d'IL-2. Corrélation avec la réponse clinique. Bull. Cancer, 79, 55-65 (1992b).
5. BLAY, J.-Y. ROSSI, J.-F., WIJDENES, J. and FAVROT, M.C., Role of IL-6 in paraneoplastic thrombocytosis. Blood, 82, 2261-2262 (1993).
6. BLAY, J.-Y., SCHEMANN, S. and FAVROT, M.C., Local production of interleukin-6 by renal adenocarcinoma in vivo. J. nat. Cancer Inst., 86, 238-239 (1994b).
7. BOT, F.J., VAN EIJK, L., BROEDERS, L., AARDEN, L.A. and LOWENBERG, B., Interleukin-6 synergizes with M-CSF in the formation of macrophage colonies from purified human marrow progenitor cells. Blood, 73, 435-437 (1989).
8. BOXER, R.J., WAISMAN, J., LIEBNER, M.M., MAMPASO, F.M. and SKINNER, D., Non-metastatic hepatic dysfunction associated with renal carcinoma. J. Urol., 119, 468-471 (1979).
9. CARACCIOLO, D., CLARK, S.C. and ROVERA, G., Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF. Blood, 73, 666-670 (1989).
10. CHATELAIN, C., BERLIERE, M., LONGUEVILLE, J., FEYENS, A.M., DE GREVE, J., VAN OOSTEROM, A., VON GRAFFENRIED, B., DONNEZ, J. and SYMANN, M., Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase-Ib study. Blood, 85, 2347-2353 (1995).
11. DOSQUET, C., SCHAETZ, A., FAUCHER, C., LEPAGE, E., WAUTIER, J.-L., RICHARD, F. and CABANE, J., Tumor necrosis factor, interleukin 1β and interleukin 6 in patients with renal-cell carcinoma. Europ. J. Cancer, 30A, 162-167 (1994).
12. EMILIE, D., WIJDENES, J., GISSELBRECHT, C., JARROUSSE, B., BILLAUD, E., BLAY, J.-Y., GABARRE, J., GAILLARD, J.-P., BROCHIER, J., RAPHAEL, M., BOUÉ, F. and GALANAUD, P., Administration of an anti-interleukin 6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma. Blood, 84, 2472-2479 (1994).
13. GAULDIE, J., RICHARDS, C., HARNISH, D., LANSDORP, P. and BAUMANN, H., Interferon beta 2/BSF2 shares identity with monocyte-derived hepatocytestimulating factor and regulates the major acute-phase protein in liver cells. Proc. nat. Acad. Sci. (Wash.), 84, 7251-7255 (1987).
14. HEINRICH, P.C., CASTELL, J.V. and ANDUS, T., Interleukin 6 and the acute-phase response. Biochem. J., 265, 621-626 (1990).
15. IKEBUCHI, K., WONG, G.G., CLARK, S.C., IHLE, J.N., HIRAI, Y. and OGAWA, M., Interleukin-6 enhancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc. nat. Acad. Sci. (Wash.), 84, 9035-9039 (1987).
16. ISHIBASHI, T., KIMURA, H., UCHIDA, T., KARIYONE, S., FRIESE, P. and BURSTEIN, S.A., Human interleukin 6 is a direct promoter of maturation of menakaryocytes in vitro. Proc. nat. Acad. Sci. (Wash.). 86, 5953-5957 (1989).
17. JACOBSEN, S.E., RUSCETTI, F.W., DUBOIS, C.M., WINE, J. and KELLER, J.R., Induction of colony-stimulating-factor-receptor expression on hematopoietic progenitor cells: proposed mechanism for growth-factor synergism. Blood 80, 678-687 (1992).
18. JANSEN, J.H., KLUIN-NELEMANS, J.C., VAN DAMME, J., WIENTJENS, G.J., WILLEMZE, R. and FIBBE, W.E., Interleukin-6 is a permissive factor for monocytic-colony formation by human hematopoietic progenitor cells. J. exp. Med., 175, 1151-1154 (1992).
19. KLEIN, B. and 13 OTHERS. Murine-anti-interleukin-6-monoclonal-antibody therapy for a patient with plasma-cell leukemia. Blood, 78, 1198-1204 (1991).
20. LOTEM, J., SHABO, Y. and SACHS, L., Regulation of megakaryocyte development by interleukin-6. Blood, 74, 1545-1551 (1989).
21. MIKI, S., IWANO, M., MIKI, Y., YAMAMOTO, M., TANG, B., YOKOKAWA, K., SONDA, T., HIRANO, T. and KISHIMOTO, T., IL-6 functions as an autocrine growth factor in renal carcinomas. FEBS Lett., 250, 607-610 (1988).
22. OLIVIHRO, S. and CORTESE, R., The human haptoglobin-gene promoter: interleukin-6-responsive elements interact with a DNA-binding protein induced by interleukin-6. EMBO J., 8, 1145-1151 (1989).
23. RAVOET, C., DE GREVE, J., VANDEWOUDE, K., KERGER, J., SCULIER, J.P., LACOR, P., STRYCKMANS, S. and PICCART, M., Tumor-stimulating effects of recombinant human IL-6. Lancet, 344, 1576-1577 (1994).
24. RENNICK, D., JACKSON, J., YANG, G., WIDEMAN, J., LEE, F. and HUDAK, S., Interleukin-6 interacts with interleukin-4 and other hematopoietic growth factors to selectively enhance the growth of megakaryocytic, erythroid, myeloid and multipotential progenitor cells. Blood, 73, 1828-1835 (1989).
25. RITCHIE, A.W.S. and CHISHOLM, G.D., The natural history of renal carcinoma. Semin. Oncol., 10, 390-400 (1983).
26. STAUFFER, M.H., Nephrogeneic hepatosplenomegaly (abstract). Gastroenterology, 40, 694 (1961)
27. TAKENAWA, J., KANAKO, Y., FUKYUMOTO, M., FUKATSU, A., HIRANO, T., FIKUYAMA, H., NAKAYAMA, H., FUJITA, J. and YOSHIDA, O., Enhanced expression of IL-6 in primary human renal-cell carcinoma. J. nat. Cancer Inst., 83, 1668-1672 (1991).
28. TSUKAMOTO, T., KUMAMOTO, Y., MIYAO, N., MASUMORI, N., TAKAHASHI, A. and YANASE, M., Interleukin-6 in renal-cell carcinoma. J. Urol., 148, 1778-1781 (1992).
29. WEBER, J., YANG, J.C., TOPALIAN, S.L., PARKINSON, D.R., SCHWARTZENDRUBER, D.S., ETTINGHAUSEN, S.E., GUNN, H., MIXON, A., KIM, H., COLE, D., LEVIN, R. and ROSENBERG, S.A., Phase-I trial of interleukin-6 in humans. J. clin. Oncol., 11, 499-506 (1993).
30. ZHAO, Y.-L., BRAILLY, H., WIJDENES, J., BATAILLE, R., ROSSI, J.-F. and KLEIN, B., Measurement of whole-body interleukin-6 production: prediction of the efficacy of anti-IL-6 treatment. Blood, 86, 3123-3131 (1995).